469 related articles for article (PubMed ID: 34740081)
41. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.
Zhang Z; Tang Y; Liu Y; Zhuang H; Lin E; Xie L; Feng X; Tian K; Zeng J; Liu J; Yu Y
J Immunol Res; 2021; 2021():9921466. PubMed ID: 34368371
[TBL] [Abstract][Full Text] [Related]
42. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
[TBL] [Abstract][Full Text] [Related]
43. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
44. Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer.
Zhou M; Lv S; Hou Y; Zhang R; Wang W; Yan Z; Li T; Gan W; Zeng Z; Zhang F; Yang M
Front Immunol; 2022; 13():994874. PubMed ID: 36330513
[TBL] [Abstract][Full Text] [Related]
45. A Tumor-Specific Prognostic Long Non-Coding RNA Signature in Gastric Cancer.
Ren W; Zhang J; Li W; Li Z; Hu S; Suo J; Ying X
Med Sci Monit; 2016 Oct; 22():3647-3657. PubMed ID: 27727196
[TBL] [Abstract][Full Text] [Related]
46. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
47. Expression status and prognostic value of autophagy-related lncRNAs in prostate cancer.
Chen G; Qin X; Wang Y; Gao B; Ling M; Yin W; Li Y; Pan B
Cell Cycle; 2022 Aug; 21(16):1684-1696. PubMed ID: 35414328
[TBL] [Abstract][Full Text] [Related]
48. Development and validation of a ferroptosis-related lncRNAs prognosis signature in colon cancer.
Cai HJ; Zhuang ZC; Wu Y; Zhang YY; Liu X; Zhuang JF; Yang YF; Gao Y; Chen B; Guan GX
Bosn J Basic Med Sci; 2021 Oct; 21(5):569-576. PubMed ID: 33714257
[TBL] [Abstract][Full Text] [Related]
49. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
50. A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma.
Huang GW; Xue YJ; Wu ZY; Xu XE; Wu JY; Cao HH; Zhu Y; He JZ; Li CQ; Li EM; Xu LY
BMC Cancer; 2018 Feb; 18(1):147. PubMed ID: 29409459
[TBL] [Abstract][Full Text] [Related]
51. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
52. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
[TBL] [Abstract][Full Text] [Related]
53. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
[TBL] [Abstract][Full Text] [Related]
54. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
55. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
56. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
57. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
Ren J; Wang A; Liu J; Yuan Q
Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
[TBL] [Abstract][Full Text] [Related]
58. Identification of a 14-lncRNA Signature and Construction of a Prognostic Nomogram Predicting Overall Survival of Gastric Cancer.
Nie K; Deng Z; Zheng Z; Wen Y; Pan J; Jiang X; Yan Y; Liu P; Liu F; Li P
DNA Cell Biol; 2020 Sep; 39(9):1532-1544. PubMed ID: 32644844
[TBL] [Abstract][Full Text] [Related]
59. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.
Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X
Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610
[TBL] [Abstract][Full Text] [Related]
60. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
Zhang X; Zhang M; Zhang X; Zhu X; Wang J
BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
